Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled study of TS-172 in hyperphosphatemia patients on hemodialysis
jRCT2031250548Phase 3Recruiting
- Sponsor
- Taisho Pharmaceutical
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hyperphosphatemia comparing TS-172 + phosphate binders with Placebo + phosphate binders (2 arms). Primary endpoint: Achievement rate of target serum phosphorus level at Week 8. Started Jan 2026; status: recruiting.
02
Drugs
TS-172
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on jRCT2031250548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250548.